## Gene Summary
PDGFRB, or Platelet-Derived Growth Factor Receptor Beta, encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are essential mitogens for fibroblast and vascular smooth muscle cells. PDGFRB is predominantly expressed in tissues such as the brain, heart, and kidneys. Mutations in this gene have been associated with developmental and proliferative disorders due to its role in cellular growth and division.

## Gene Drugs, Diseases, Phenotypes, and Pathways
PDGFRB is implicated in various diseases, prominently in cancers due to its role in cell proliferation and angiogenesis. Mutations or dysregulation of PDGFRB are linked to diseases like dermatofibrosarcoma protuberans, gastrointestinal stromal tumors, and familial idiopathic basal ganglia calcification. In these pathologies, PDGFRB expression influences tumor growth dynamics and vascular development. It is also a critical player in several signaling pathways, including the PI3K-Akt signaling pathway, which is vital for cell survival and growth.

## Pharmacogenetics
The pharmacogenetic aspects of PDGFRB involve its interactions with drugs that target tyrosine kinase receptors. Specific inhibitors, such as Imatinib, Sunitinib, and Sorafenib, used in the treatment of GIST, leukemia, and other malignancies, highlight the importance of PDGFRB as a drug target. The efficacy and toxicity of these drugs can vary based on genetic variations in PDGFRB, influencing the personalized treatment strategies. Knowledge of PDGFRB gene variants can assist in optimizing therapy effectiveness and managing adverse effects in cancer treatment regimes.